- The trial at Kyoto University Hospital evaluated allogeneic induced pluripotent stem cell-derived dopaminergic progenitor transplants in Parkinson’s disease patients.
- Safety was demonstrated with no serious adverse events reported, and potential clinical benefits were observed, including improvements in motor symptoms and dopamine production.
- Fluorine-18-l-dihydroxyphenylalanine (18F-DOPA) PET imaging confirmed dopamine production.
- Tacrolimus was used for immunosuppression in the patients.
- The trial marked the first clinical study of iPSCs for Parkinson’s disease, showing early indications of efficacy.
Source: Nature
